Overall, these studies suggest that therapeutic targeting of Hippo signaling for AD should aim to inhibit Hippo kinases or increase YAP levels; however, two studies in neuronal cell lines and C. elegans models present results implying that hypo-Hippo signaling could also exacerbate AD pathology, highlighting the need to clarify the context-dependent nature of Hippo signaling in AD. The gene discussed is YAP1; the disease is Alzheimer disease.